iSpecimen Inc. cash flow to debt ratio of -1.58K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

iSpecimen Inc.'s free cash flow has increased -48.87% from $-8.30M last year to $-4.24M, signaling increasing performance

iSpecimen Inc.'s debt to equity ratio is 0.31, which means that the company's assets are healthy financed, signaling financial stability.

iSpecimen Inc.'s debt has increased relative to shareholder equity from 0.09 last year to 0.31 today, signaling weakened financials

iSpecimen Inc. has a net cash position, so leverage is healthy.

iSpecimen Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

iSpecimen Inc.'s profit margin has decreased (703.43%) in the last year from -134.51% to -1.08K%, signaling decreasing performance

iSpecimen Inc.'s short-term assets of $6.95M exceed its short-term liabilities of $6.23M

iSpecimen Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

iSpecimen Inc.'s return on equity of -584.67%, is lower than 15.00%, indicating bad performance

iSpecimen Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

iSpecimen Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

iSpecimen Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

iSpecimen Inc. has negative free cash flow, indicating cash burn

iSpecimen Inc.'s yearly earnings has increased -16.09% since last year from $-12.50M to $-10.49M, signaling increasing performance

iSpecimen Inc.'s yearly revenue has decreased 79.24% since last year from $9.29M to $1.93M, signaling decreasing performance

ROIC -924.01% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

iSpecimen Inc.'s 3-year revenue CAGR of -42.97% is negative, indicating declining revenue over the past 3 years

iSpecimen Inc. had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

iSpecimen Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

iSpecimen Inc. has insufficient data to evaluate this check.

iSpecimen Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

iSpecimen Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

iSpecimen Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

iSpecimen Inc. has insufficient data to evaluate this check.

iSpecimen Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

iSpecimen Inc. has a price-to-book ratio of 0.01x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

iSpecimen Inc. has a price-to-sales ratio of 0.01x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue